{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219398","form_type":"8-K","ticker":"MAZE","cik":"0001842295","company_name":"Maze Therapeutics, Inc.","filed_at":"2026-05-12T20:07:51+00:00","discovered_at":"2026-05-12T20:09:01.315855+00:00","generated_at":"2026-05-12T21:24:38.687659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Maze Q1 net loss $24.2M; MZE829 reduces proteinuria 35.6% in Phase 2 AMKD trial","bullets":["MZE829 Phase 2 HORIZON: 35.6% mean uACR reduction at week 12 in broad AMKD; 50% of patients had >30% reduction; no serious AEs.","In severe FSGS subgroup, MZE829 achieved 61.8% mean uACR reduction; in non-diabetic AMKD, 48.6% reduction.","Cash $362.9M at March 31, 2026; April 2026 raised ~$150M in offering plus $20M milestone from Shionogi; runway into 2029.","Net loss $24.2M ($0.45/share) vs $32.8M ($1.15) YoY; license revenue $20M; R&D $34.1M, G&A $12.4M.","MZE782 Phase 2 in PKU to start mid-2026 with topline data in 2027; Phase 2 in CKD expected H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219398","json":"https://secwatch.observer/filing/0001193125-26-219398.json","markdown":"https://secwatch.observer/filing/0001193125-26-219398.md","text":"https://secwatch.observer/filing/0001193125-26-219398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/0001193125-26-219398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:24:38.687659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}